Evidence map›Paper›PMID 33205035›Full record

ReviewJHEP reports : innovation in hepatology2021

New insights into the pathophysiology and clinical care of rare primary liver cancers.

Elia Gigante, Valérie Paradis, Maxime Ronot, François Cauchy, Olivier Soubrane, Nathalie Ganne-Carrié, Jean-Charles Nault

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.International journal of molecular sciences · 2023
    Review
  18. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elia GiganteService d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
Valérie ParadisCentre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149 « De l'inflammation au cancer », Paris, France.
Maxime RonotCentre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149 « De l'inflammation au cancer », Paris, France.
François CauchyCentre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149 « De l'inflammation au cancer », Paris, France.
Olivier SoubraneCentre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149 « De l'inflammation au cancer », Paris, France.
Nathalie Ganne-CarriéService d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
Jean-Charles NaultService d'hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic haemangioendothelioma and hepatic angiosarcoma represent less than 5% of primary liver cancers. Fibrolamellar carcinoma and hepatic haemangioendothelioma are driven by unique somatic genetic alterations (

Indexed as

5-FU, 5-FluorouracilAFP, alpha-fetoproteinAPHE, arterial phase hyperenhancementCA19-9, carbohydrate antigen 19-9CCA, cholangiocarcinomaCEUS, contrast-enhanced ultrasoundcHCC-CCA, combined hepatocholangiocarcinomaCK, cytokeratinCLC, cholangiolocellular carcinomaEpCAM, epithelial cell adhesion moleculeFibrolamellar carcinomaFISH, fluorescence in situ hybridisationFLC, fibrolamellar carcinomaHAS, hepatic angiosarcomaHCC, hepatocellular carcinomaHEH, hepatic epithelioid haemangioendotheliomaHepatic angiosarcomaHepatic hemangioendotheliomaHepatocellular carcinomaHepatocholangiocarcinomaHepPar1, hepatocyte specific antigen antibodyiCCA, intrahepatic cholangiocarcinomaIHC, immunohistochemistryLI-RADS, liver imaging reporting and data systemLT, liver transplantationMixed tumorRT-PCR, reverse transcription PCRSIRT, selective internal radiation therapyTACE, transarterial chemoembolisationWHO, World Health Organization

Identifiers

PMID33205035
PMCPMC7653076
OpenAlexW3080101105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.